In the coronavirus efficacy (COVE) phase 3 clinical trial, vaccine recipients were assessed
for neutralizing and binding antibodies as correlates of risk for COVID-19 disease and as …

The TZM-bl assay measures antibody-mediated neutralization of HIV-1 as a function of
reductions in HIV-1 Tat-regulated firefly luciferase (Luc) reporter gene expression after a single …

Standardized assessments of HIV-1 vaccine-elicited neutralizing antibody responses are
complicated by the genetic and antigenic variability of the viral envelope glycoproteins (Envs). …

The best assay or marker to define mRNA-1273 vaccine–induced antibodies as a correlate
of protection (CoP) is unclear. In the COVE trial, participants received two doses of the mRNA…

Background Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which
comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These …

Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated
with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of …

Despite the wide availability of antiretroviral drugs, more than 250,000 infants are vertically
infected with HIV-1 annually, emphasizing the need for additional interventions to eliminate …

Recent advances in assay technology have led to major improvements in how HIV-1
neutralizing antibodies are measured. A luciferase reporter gene assay performed in TZM-bl (…

Purpose Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic
cause characterized by profound deficiencies of T, B and sometimes NK cell function. Non-…

Severe combined immunodeficiency (SCID) is a syndrome of diverse genetic cause characterized
by profound deficiencies of T, B, and sometimes NK-cell function. Nonablative human …